SciCombinator

Discover the most talked about and latest scientific content & concepts.

CL Hager, EL Larkin, L Long, FZ Abidi, KJ Shaw and MA Ghannoum
Abstract
Candida auris is an emerging multidrug-resistant yeast that has been responsible for invasive infections associated with high morbidity and mortality. C. auris strains often demonstrate high fluconazole and amphotericin B minimum inhibitory concentration values, and some strains are resistant to all 3 major antifungal classes. Here we evaluated the susceptibility of 16 C. auris clinical strains, isolated from a wide geographical area, to 10 antifungal agents including APX001A, a novel agent that inhibits the fungal protein Gwt1 (GPI-anchored wall transfer protein 1). APX001A demonstrated significantly lower MIC50 and MIC90 values (0.004 μg/mL and 0.031 μg/mL, respectively) than all other agents tested.The efficacy of the prodrug APX001 was evaluated in an immunocompromised murine model of disseminated C. auris infection. Significant efficacy (80%-100% survival) was observed in all three APX001 treatment groups versus 50% survival for the anidulafungin treatment group. In addition, APX001 showed a significant log reduction in colony forming units (CFU) counts in kidney, lung and brain tissue (1.03 to 1.83) versus the vehicle control. Anidulafungin also showed a significant log reduction in CFU in kidney and lung (1.5 and 1.62, respectively), but did not impact brain CFU. These data support further clinical evaluation of this new antifungal agent.
Tweets*
12
Facebook likes*
0
Reddit*
0
News coverage*
10
Blogs*
1
SC clicks
0
Concepts
In vitro, Echinocandin, Fluconazole, Antifungal drug, Ergosterol, Flucytosine, Candidiasis, Antifungals
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com